Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by JMark80on Jul 20, 2020 11:37am
121 Views
Post# 31290684

RE:RE:RE:RE:RE:RE:Retail investors didn’t even get the opportunity to vote re

RE:RE:RE:RE:RE:RE:Retail investors didn’t even get the opportunity to vote re
Jack4000 wrote:

 

JMark80 wrote: Market for chlorine gas treatment is miniscule.

 

Better tell the DHS that as they think it's of paramount importance seeing as how it's one of the events they fear as per the National Planning Scenario case in point - chorline plants were among the targets Mohamed Atta scoped out prior to 911.

https://www.ajg.com/us/-/media/files/us/legacy/national-planning-scenarios-executive-summaries.pdf

But what do they know huh.  COVID has shown us they lack ventilators, C pap devices even when the casualties can get to hospitals so I'm sure they can administer something in a secondary contamination location right next to a mass casualty event location?

What is it that they would use since you think it won't be R-107?

 

JMark80 wrote: Salzman does not need to be publicly traded at all. 

 

Of course they don't.  I mean, why would they want to have money to market their stuff to the rest of the world since nobody but the US makes plastic, paper, cleaning supplies or disinfectents or have water treatment plants - all of which require vast amounts of chlorine to be stored and transported to them right? 

As for no market for CILI treatment tell the people of Graniteville SC who were victims of a chlorine spill in 2006.  They might wonder if you have a clue or not.  Or the EPA who said;

“ A suburban California chemical plant routinely loads chlorine into 90-ton railroad cars that, if ruptured, could poison more than 4 million people in Orange and Los Angeles counties, depending on wind speed, direction and the ambient temperature.” 

“A South Kearny, N.J., chemical company's 180,000 pounds of chlorine or sulfur dioxide could form a cloud that could threaten 12 million people.”

“The Atofina Chemicals Inc. plant outside Detroit projects that a rupture of one of its 90-ton rail cars of chlorine could endanger 3 million people.” 

 

JMark80 wrote: He knew it was only way for Kaly to continue and for him to keep his cushy job. 

 

I suppose you can tell us all how he was getting paid in this 'cushy job' since last December since Kaly hasn't t had any money?

Please, we're all ears.  Go ahead.



How many doses will they stockpile, 100k per their theoretical contingency from 2005? That is absolutely miniscule. Besides, if they're already paying $80mm to develop, how much on top will they pay for sales, if anything? Noticed you completely ignored that detail.

You literally said Salzman needs to be publicly traded. Salzman doesn't need to be publicly traded to raise capital. Kaly had to pay Salzman in shares (which they dumped) because they couldn't get funding, now they're propositioning stockhouse members.

So Kaly is broke? I must have missed the PR that said Farrell was working for free, or maybe he's accepting shares for payment?
<< Previous
Bullboard Posts
Next >>